REGENHU-Switzerland-3d-bioprinting-instrument-bio-3d-bioprinter-DevelopmentTeam-0006

SCIENTIFIC PUBLICATIONS

You are researching: Epithelial
Matching entries: 4 /4
All Groups
AUTHOR Estermann, Manuela and Bisig, Christoph and Septiadi, Dedy and Petri-Fink, Alke and Rothen-Rutishauser, Barbara
Title Bioprinting for Human Respiratory and Gastrointestinal In Vitro Models [Abstract]
Year 2020
Journal/Proceedings
Reftype
DOI/URL DOI
Abstract
Increasing ethical and biological concerns require a paradigm shift toward animal-free testing strategies for drug testing and hazard assessments. To this end, the application of bioprinting technology in the field of biomedicine is driving a rapid progress in tissue engineering. In particular, standardized and reproducible in vitro models produced by three-dimensional (3D) bioprinting technique represent a possible alternative to animal models, enabling in vitro studies relevant to in vivo conditions. The innovative approach of 3D bioprinting allows a spatially controlled deposition of cells and biomaterial in a layer-by-layer fashion providing a platform for engineering reproducible models. However, despite the promising and revolutionizing character of 3D bioprinting technology, standardized protocols providing detailed instructions are lacking. Here, we provide a protocol for the automatized printing of simple alveolar, bronchial, and intestine epithelial cell layers as the basis for more complex respiratory and gastrointestinal tissue models. Such systems will be useful for high-throughput toxicity screening and drug efficacy evaluation.
AUTHOR Šimková, Kateřina and Thormann, Ursula and Imanidis, Georgios
Title Investigation of drug dissolution and uptake from low-density DPI formulations in an impactor–integrated cell culture model [Abstract]
Year 2020
Journal/Proceedings European Journal of Pharmaceutics and Biopharmaceutics
Reftype
DOI/URL URL DOI
Abstract
Besides deposition, pulmonary bioavailability is determined by dissolution of particles in the scarce epithelial fluid and by cellular API uptake. In the present work, we have developed an experimental in vitro model, which is combining the state-of-the-art next generation impactor (NGI), used for aerodynamic performance assessment of inhalation products, with a culture of human alveolar A549 epithelial cells to study the fate of inhaled drugs following lung deposition. The goal was to investigate five previously developed nano-milled and spray-dried budesonide formulations and to examine the suitability of the in vitro test model. The NGI dissolution cups of stages 3, 4, and 5 were transformed to accommodate cell culture inserts while assuring minimal interference with the air flow. A549 cells were cultivated at the air–liquid interface on Corning® Matrigel® -coated inserts. After deposition of aerodynamically classified powders on the cell cultures, budesonide amount was determined on the cell surface, in the interior of the cell monolayer, and in the basal solution for four to eight hours. Significant differences in the total deposited drug amount and the amount remaining on the cell surface at the end of the experiment were found between different formulations and NGI stages. Roughly 50% of budesonide was taken up by the cells and converted to a large extent to its metabolic conjugate with oleic acid for all formulations and stages. Prolonged time required for complete drug dissolution and cell uptake in case of large deposited powder amounts suggested initial drug saturation of the surfactant layer of the cell surface. Discrimination between formulations with respect to time scale of dissolution and cell uptake was possible with the present test model providing useful insights into the biopharmaceutical performance of developed formulations that may be relevant for predicting local bioavailability. The absolute quantitative result of cell uptake and permeation into the systemic compartment is unreliable, though, because of partly compromised cell membrane integrity due to particle impaction and professed leakiness of A549 monolayer tight junctions, respectively.
AUTHOR Raphael, Bella and Khalil, Tony and Workman, Victoria L. and Smith, Andrew and Brown, Cameron P. and Streulli, Charles and Saiani, Alberto and Domingos, Marco
Title 3D cell bioprinting of self-assembling peptide-based hydrogels [Abstract]
Year 2016
Journal/Proceedings Materials Letters
Reftype
DOI/URL URL DOI
Abstract
Abstract Bioprinting of 3D cell-laden constructs with well-defined architectures and controlled spatial distribution of cells is gaining importance in the field of Tissue Engineering. New 3D tissue models are being developed to study the complex cellular interactions that take place during both tissue development and in the regeneration of damaged and/or diseased tissues. Despite advances in 3D printing technologies, suitable hydrogels or 'bioinks' with enhanced printability and cell viability are lacking. Here we report a study on the 3D bioprinting of a novel group of self-assembling peptide-based hydrogels. Our results demonstrate the ability of the system to print well-defined 3D cell laden constructs with variable stiffness and improved structural integrity, whilst providing a cell-friendly extracellular matrix “like” microenvironment. Biological assays reveal that mammary epithelial cells remain viable after 7 days of in vitro culture, independent of the hydrogel stiffness.
AUTHOR Horvath, Lenke and Umehara, Yuki and Jud, Corinne and Blank, Fabian and Petri-Fink, Alke and Rothen-Rutishauser, Barbara
Title Engineering an in vitro air-blood barrier by 3D bioprinting. [Abstract]
Year 2015
Journal/Proceedings Scientific reports
Reftype
DOI/URL URL
Abstract
Intensive efforts in recent years to develop and commercialize in vitro alternatives in the field of risk assessment have yielded new promising two- and three dimensional (3D) cell culture models. Nevertheless, a realistic 3D in vitro alveolar model is not available yet. Here we report on the biofabrication of the human air-blood tissue barrier analogue composed of an endothelial cell, basement membrane and epithelial cell layer by using a bioprinting technology. In contrary to the manual method, we demonstrate that this technique enables automatized and reproducible creation of thinner and more homogeneous cell layers, which is required for an optimal air-blood tissue barrier. This bioprinting platform will offer an excellent tool to engineer an advanced 3D lung model for high-throughput screening for safety assessment and drug efficacy testing.